Hematology News

ATLANTA — Reliance on use of the ED for pain among children with sickle cell disease appeared below the threshold for excessive reliance, according to results of a study conducted in Wisconsin presented at the ASH Annual Meeting and Exposition.

ATLANTA — Opioid use among younger patients with sickle cell disease remained steady over time, according to findings presented at the ASH Annual Meeting and Exposition.

ATLANTA — Treatment with voxelotor appeared associated with considerable improvement in hemoglobin and reduced clinical measures of hemolysis among adolescents with sickle cell disease, according to preliminary phase 2a study results presented at the ASH Annual Meeting and Exposition.

ATLANTA — A gene therapy approach resulted in sustained, clinically relevant factor VIII activity for certain patients with severe hemophilia A, according to study results presented at ASH Annual Meeting and Exposition.

ATLANTA —Patients with cancer at risk for recurrent venous thromboembolism appeared less likely to experience recurrence with rivaroxaban than dalteparin, according to results of a pilot study presented at the ASH Annual Meeting and Exposition.

ATLANTA — Emicizumab-kxwh prophylaxis prevented or considerably reduced bleeds among pediatric patients with hemophilia A with inhibitors, according to results of a phase 3 study presented at the ASH Annual Meeting and Exposition.

Emicizumab-kxwh prophylaxis administered once every 4 weeks conferred clinically meaningful bleeding control among patients aged 12 years and older with hemophilia A, according to study results released by the agent’s manufacturer.

A one-time IV infusion of gene therapy with SPK-9001 appeared associated with sustained level of factor IX coagulant activity of approximately 30% among adult men with hemophilia B, according to results from an open-label, nonrandomized phase 1/phase 2a clinical study.

ASH will present awards to former Vice President Joe Biden, as well as journalist and author Tom Brokaw, in recognition of their advocacy for biomedical research and hematology.

ASH announced the recipients of the society’s 2018 Scholar Awards.